US11103576B1ActiveUtility

Measles virus vaccine expressing SARS-COV-2 protein(s)

86
Assignee: UNIV OF PITTSBURGH—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATIONPriority: Jun 15, 2020Filed: Sep 2, 2020Granted: Aug 31, 2021
Est. expiryJun 15, 2040(~13.9 yrs left)· nominal 20-yr term from priority
Inventors:William Paul Duprex
C12N 2770/20022C07K 14/005C12N 15/86C12N 2770/20034C12N 2760/18443C12N 2760/18434A61P 31/14A61K 2039/575A61K 2039/572A61K 2039/53A61K 2039/5256A61K 39/12C12N 7/00A61K 39/215A61K 39/165
86
PatentIndex Score
3
Cited by
9
References
10
Claims

Abstract

A recombinant measles viral vector comprising a nucleic acid sequence encoding a Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) spike glycoprotein is provided. Polypeptides comprising the SARS-CoV-2 spike glycoprotein also are provided, as well as related nucleic acids, vectors, and compositions. The polypeptides, nucleic acids, vectors, and compositions can be used in methods of preventing, inhibiting, reducing, eliminating, protecting, or delaying the onset of an infection or an infectious clinical condition caused by coronavirus and methods for inducing an immune response against a coronavirus.

Claims

exact text as granted — not AI-modified
The invention claimed is: 
     
       1. A recombinant measles viral vector comprising a nucleic acid sequence encoding a Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) spike glycoprotein, wherein the nucleic acid sequence contains at least one modification that disrupts the endoplasmic reticulum (ER) retention sequence of the SARS-CoV-2 spike glycoprotein. 
     
     
       2. The recombinant measles viral vector of  claim 1 , wherein the ER retention sequence of the SARS-CoV-2 spike glycoprotein contains AxAxx rather than KxHxx in the cytoplasmic tail. 
     
     
       3. The recombinant measles viral vector of  claim 1 , wherein the nucleic acid sequence encoding the SARS-CoV-2 spike glycoprotein is SEQ ID NO: 3 (S-CO-AA). 
     
     
       4. The recombinant measles viral vector of  claim 1 , wherein the amino acid sequence of the SARS-CoV-2 spike glycoprotein is SEQ ID NO: 10 (S-CO-AA). 
     
     
       5. The recombinant measles viral vector of  claim 1 , comprising the nucleic acid sequence of SEQ ID NO: 17 (SARS-CoV-2-S-CO-AA). 
     
     
       6. A pharmaceutical composition comprising the recombinant measles viral vector of  claim 1  and a pharmaceutically acceptable carrier. 
     
     
       7. A nucleic acid encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 10 (S-CO-AA). 
     
     
       8. A nucleic acid comprising the nucleic acid sequence of SEQ ID NO: 3 (S-CO-AA). 
     
     
       9. A recombinant vector comprising the nucleic acid of  claim 7 . 
     
     
       10. A pharmaceutical composition comprising (i) the nucleic acid of  claim 7  and (ii) a pharmaceutically acceptable carrier.

Join the waitlist — get patent alerts

Track US11103576B1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.